Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:35:30.883Z.
Calculation as of: 2026-10-06T15:35:30.883Z.
Quote observation: 2026-10-06T15:34:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3eea2ebb4dfb8ae449a8fc068c41cc3e6d53bf63d9a404ece64f578f5b067b33
PEG RATIO
N/A
Altimmune, Inc.
Market Cap
$522.16M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Altimmune, Inc. (ALT) | $522.16M | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $524.20M | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $525.22M | N/A |
| 908 Devices Inc. (MASS)vs › | $514.28M | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $510.83M | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $537.18M | N/A |
| ProKidney Corp. (PROK)vs › | $538.01M | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $538.58M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $540.95M | N/A |
| Oculis Holding AG (OCS)vs › | $500.37M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
